Literature DB >> 16139434

Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City.

Sandro Galea1, Nancy Worthington, Tinka Markham Piper, Vijay V Nandi, Matt Curtis, David M Rosenthal.   

Abstract

INTRODUCTION: Naloxone, an opiate antagonist that can avert opiate overdose morality, has long been prescribed to drug users in Europe and in a few US cities. However, there has been little documented evidence of naloxone distribution programs and their feasibility in the peer reviewed literature in the US.
METHODS: A pilot overdose prevention and reversal program was implemented in a New York City syringe exchange program. We assessed demographics, drug use, and overdose history, experience, and behavior at baseline, when participants returned for prescription refills, and 3 months after baseline assessment.
RESULTS: 25 participants were recruited. 22 (88%) participants were successfully followed-up in the first 3 months; of these, 11 (50%) participants reported witnessing a total of 26 overdoses during the follow-up period. Among 17 most-recent overdoses witnessed, naloxone was administered 10 times; all persons who had naloxone administered lived. DISCUSSION: Naloxone administration by injection drug users is feasible as part of a comprehensive overdose prevention strategy and may be a practicable way to reduce overdose deaths on a larger scale.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139434     DOI: 10.1016/j.addbeh.2005.07.020

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  56 in total

1.  High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users.

Authors:  David Frank; Pedro Mateu-Gelabert; Honoria Guarino; Alex Bennett; Travis Wendel; Lauren Jessell; Anastasia Teper
Journal:  Int J Drug Policy       Date:  2014-07-31

Review 2.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

3.  Preventing opiate overdose deaths: examining objections to take-home naloxone.

Authors:  Alexander R Bazazi; Nickolas D Zaller; Jeannia J Fu; Josiah D Rich
Journal:  J Health Care Poor Underserved       Date:  2010-11

4.  Providing naloxone to substance users for secondary administration to reduce overdose mortality in New York City.

Authors:  Daliah I Heller; Sharon Stancliff
Journal:  Public Health Rep       Date:  2007 May-Jun       Impact factor: 2.792

Review 5.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

6.  Schwartz et al. respond.

Authors:  Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild K Olsen; Shannon Gwin Mitchell; Jerome H Jaffe
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

7.  Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose?

Authors:  Stephen Koester; Shane R Mueller; Lisa Raville; Sig Langegger; Ingrid A Binswanger
Journal:  Int J Drug Policy       Date:  2017-07-19

Review 8.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

9.  Injection drug users trained by overdose prevention programs: responses to witnessed overdoses.

Authors:  Stephen E Lankenau; Karla D Wagner; Karol Silva; Aleksandar Kecojevic; Ellen Iverson; Miles McNeely; Alex H Kral
Journal:  J Community Health       Date:  2013-02

10.  Overdose prevention and naloxone prescription for opioid users in San Francisco.

Authors:  Lauren Enteen; Joanna Bauer; Rachel McLean; Eliza Wheeler; Emalie Huriaux; Alex H Kral; Joshua D Bamberger
Journal:  J Urban Health       Date:  2010-12       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.